† 864 ISOLATED THROMBOCYTOPENIA FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION. LR First, BR Smith, JM Lipton, DG Nathan, RP Parkman, JM Rapoport. Harvard Medical School, Departments of Medicine and Pediatrics, Boston, MA.

Isolated thrombocytopenia following bone marrow transplantation was investigated in 65 fully grafted patients (pts) surviving 60 days post transplant. 24 pts (37%) developed this complication, which occurred most frequently in pts receiving pre-tx preparation with total body irradiation or busulfan. Two distinct syndromes were identified: (1) transient thrombocytopenia (9 pts) in which a normal platelet (plt) count ($100,000/\text{mm}^3$) was established by day +40 but then fell to $10-45,000$ on day +40-+70, with subsequent resolution by day +90. Three of these cases were associated with trimethoprim-sulfamethoxazole therapy. (2) chronic thrombocytopenia (15 pts) in which a plt count $>100,000$ was not achieved at any time during the first 4 mo post-tx despite the simultaneous presence of normal granulocyte and reticulocyte counts. No association with drug therapy was detected. While the transient syndrome did not adversely affect prognosis, the chronic syndrome carried a high mortality (21% actuarial survival at 1000 days post-tx compared to 67% for all other pts $p<0.01$). The mortality was not due to bleeding but rather to a high association with both severe acute (grade III-IV) graft versus host disease and chronic GVHD. We conclude that isolated thrombocytopenia represents a significant complication of bone marrow transplantation particularly in pts receiving hematopoietic ablative preparatory regimens and that it is the chronic, and not the transient, thrombocytopenic syndrome that adversely affects patient prognosis as a manifestation of GVHD.

865 ISOLATED CHOROIDAL RELAPSE DURING COMPLETE REMISSION IN ACUTE LYMPHOCYTIC LEUKEMIA (ALL). L. S. FRANKEL, M. H. MAOR, L. P. STEAHLY, R. A. TANG, & H.G. TAYLOR, DEPTS. OF PEDIATRICS, RADIOLOGY AND OPHTHALMOLOGY AT THE M. D. ANDERSON HOSPITAL AND TUMOR INSTITUTE, HOUSTON, TEXAS 77030.

Leukemic ophthalmopathy is often reported at autopsy. Antemortem diagnosis of ocular leukemia is much less common and has been reported associated with central nervous system (CNS) &/or multiple bone marrow (BM) relapses. Leukemia was diagnosed in the choroid of a patient (pt) with ALL in complete remission (CR) during therapy. An 11 yo Black girl had null cell ALL, CaLLa and Ia positive. The CNS had no evidence of disease. Initial therapy was "standard treatment". Six mos after diagnosis the pt complained of decreased visual acuity and was found to have perivascular leukemic deposition in the ocular fundi. Fluorescein angiography and ultrasonography of the globe verified infiltration with bilateral thickening of the choroid layer. BM and spinal fluid examination were normal. Cranial radiotherapy (XRT), was administered to the whole brain, including the posterior pole of the eyes. The pt continued systemic therapy. In the 9 mos since XRT: vision has improved, fluorescein angiography shows residual pigmentary changes, ultrasonography reveals normalization of the choroid, & the pt remains in CR. Leukemic relapse of the choroid is a dangerous sanctuary not accessible to biopsy. Standard ophthalmoscopic examination provides an adequate view of only the posterior pole; without dilation, peripheral lesions cannot be seen. Since peripheral fundal lesions are generally asymptomatic, ophthalmologic consultation is indicated at diagnosis, periodically throughout treatment, & at termination of therapy for ALL.

866 ANTIPROLIFERATIVE PROPERTIES OF GENE-CLONED ALPHA INTERFERON IN ACUTE LEUKEMIA. Melvin H. Freedman, Bryan Williams, and Erwin W. Gelfand. Univ of Toronto, Hosp for Sick Children, Divs of Hematology, Infectious Diseases, and Immunology, Toronto, Canada.

The properties of recombinant-DNA human leukocyte interferon (HuINF α_2 , Schering-Plough Corp) were studied in children with advanced acute leukemia (1 each of AML, T-cell ALL, and non-T-non-B ALL). When marrow blasts were exposed to IFN in vitro, there was a marked rise in cellular 2-5A synthetase comparable to control marrow, indicating full expression of IFN receptor sites on these cells as well as their ability to react metabolically. IFN also induced a striking dose-responsive decline in leukemic blast progenitor colony formation and on blast self-renewal in vitro, confirming its antiproliferative effect. When the patients were given high-dose IFN alone (up to 100×10^6 u/m 2 I.V.), blast cytorreduction was seen in peripheral blood in all, and in marrow of the AML. Also after IFN was given, marrow and peripheral blood cells demonstrated elevated 2-5A synthetase activity in vivo, similar to the effect seen in vitro. No modulation of leukemic cell markers was seen following in vitro or in vivo treatment with IFN, implying that cytorreduction was not linked to blast differentiation. These studies suggest that this subtype of gene-cloned IFN has anti-leukemic properties, and indicates the possibilities for IFN as an adjunctive form of therapy in childhood leukemia.

867 EFFECT OF DANAZOL ON APTT, COAGULANT FACTOR ACTIVITY AND BLEEDING IN HEMOPHILIA. Harinder S. Garewal, James J. Corrigan, Jr. Brian G. M. Durie, Monette Jeter, Mary Lou Damiano. Depts. of Pediatrics and Internal Medicine, University of Arizona Health Sciences Center, Tucson.

Danazol has been reported to raise several plasma proteins. Danazol was given orally at 600 mg/day in 3 divided doses to 6 hemophiliacs for 8-14 weeks. Factor levels, APTT and other laboratory parameters were measured every 2 weeks. Five patients had classic hemophilia (1 mild-moderate, 3 severe, 1 with inhibitor) and 1 had Christmas disease. All patients showed a significant decrease in APTT beginning with the first measurement (2 weeks) and persisting till the drug was discontinued. However, a corresponding increase in the deficient factor activity could not be consistently demonstrated. Typical results for a severe classic hemophiliac are shown.

APTT(secs)		Factor VIII C (U/dl)	
Baseline	On Danazol (mean)	Baseline	On Danazol (mean)
90	64	1.1	2.0

Despite the shortened APTT bleeding episodes continued in the severe hemophiliacs and the patient with Christmas disease. In 4 patients bleeding appeared to either increase in severity or change in pattern. In 2 patients bleeding did not respond to their usual factor infusions, but responded to discontinuation of danazol and further factor replacement. In 3 patients the drug was discontinued because of bleeding. These results differ from those recently reported. Increased fibrinolytic activity may be responsible for the altered bleeding.

868 IMMUNOLOGICAL EVALUATION OF PATIENTS WITH HEMOPHILIA-R. Gera, Z. Jin, R. Cleveland, D. Murray, R. Kulkarni, E. Romond, and D.B. Kaufman. Department of Pediatrics/Human Development, East Lansing, MI and Regional Great Lake Red Cross Blood Center, Lansing, MI.

AIDS is characterized by defects in the cell mediated immune system resulting in unusual infections, neoplasms and immune phenomena. Patients with hemophilia A (HemA) treated with lyophilized commercial FVIII (Lyoph-c) are at risk of developing AIDS since many have AIDS like defects. We have studied 41 patients with hemophilia and Von Willebrand's disease (VWD): 8 Hem A treated with Lyoph-c, 7 Hem A treated with lyophilized volunteer plasma FVIII (Lyoph-v), 8 Hem A with inhibitor (Hem A-inh) and 10 Hem B treated with activated or nonactivated prothrombin complex (PTC a/n) and 8 untreated Hem A and VWD. Overall 41% had T helper/T suppressor ($OK T_H/T_{\phi}$) ratios less than 1.4. Although this defect was most marked in the lyoph-c and lyoph-v group (8/15 abnormal), a similar defect was observed in Hem A-inh (3/8), Hem B (2/10) and untreated (4/8) groups. Only two patients with abnormal T_H/T_{ϕ} had laboratory evidence of ongoing viral activity. Serum Beta-2-microglobulin (β_2m) levels were elevated (greater than 2000 $\mu\text{g/L}$) in 93% of treated patients and in only 12.5% of untreated patients. Lymphocyte blastogenesis and MLC were normal in most of the patients. There was no correlation between T cell markers (T_H/T_{ϕ} ; T_{ϕ}/T_H ; $T_{\phi}\%$; $T_H\%$) and amount of factor used. Our results indicate that immunologic abnormalities are present in hemophiliacs & VWD, and that all such patients may be at risk for developing AIDS. Elevated β_2m in treated group may reflect chronic antigenic stimulation in these patients.

869 A REEVALUATION OF THE BLEEDING TIME: J.M. Gerrard, S.J. Israels, M. Cheang, A.J. Bishop, H.L. Rayner, N.L. Kobrinsky, M.L. Schroeder and E.D. Israels. Departments of Pediatrics, Medicine and Computer Science, University of Manitoba, Winnipeg, Manitoba, Canada.

A multivariate analysis of results of 512 individuals, (more than half less than 20 years of age) referred to the University of Manitoba Coagulation Laboratory, was performed to assess the relationship of age, sex, and various coagulation parameters to the length of the bleeding time (BT). Patient age (children had longer BTs than adults, even with other factors normal), platelet aggregation to collagen and epinephrine, platelet adhesion (ADH) and prothrombin consumption (PC) emerged as important and independent variables ($p<0.01$). Controlling for other variables, including von Willebrand (vW) Ag and ristocetin cofactor (RC), did not change the correlation of ADH and BT, but decreased that between PC and BT. Where vWAg, vWRC and factor VIII were all less than 120%, there was a weak negative correlation between the length of the BT and vWAg or vWRC. In contrast, where any one of these three parameters was 120% or greater, there was a weak positive correlation between vWAg or vWRC and the BT. However, the mean BT of all (8) patients with vWAg or vWRC less than 55%, normal aggregation and PC greater than 80%, was in the normal range (7.56 min). The view that vWAg level, or activity as assessed by vWRC, is, by itself, a major determinant of the length of the BT should be revised. Platelet adhesion, independent of factor level (vWAg) or activity (vWRC) appears more important.